Table 1.
Sensitivity of SHIV-C strains to soluble CD4, human nmAbs, and serum samples
| IC50 (µg/ml) in TZM-bl cells1 | IC50 (reciprocal serum dilution) in TZM-bl cells1 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SHIV-C strain | sCD4 | IgG1b12 | 2G12 | 2F5 | 4E10 | HIVIG | BB47 | BB55 | BB68 | BB75 | BB80 | BB81 | BB87 | Tier |
| SHIV-1157ipEL (parental infectious mol. clone with early env) | 1.7 | 0.7 | >25 | >25 | >25 | 88.6 | 4274 | 3286 | 666 | 1245 | 1822 | 691 | 3278 | 1 |
| SHIV-1157ipEL-p (passaged biologic isolate with early env) | 0.5 | 1.4 | >25 | >25 | >25 | 150.8 | 1193 | 1792 | 653 | 824 | 1135 | 427 | 2707 | 1 |
| SHIV-1157ipd3N42 (infectious mol. clone with late env) | 0.4 | 7.0 | >25 | >25 | >25 | 1160 | 105 | 131 | 86 | 79 | 72 | 47 | 260 | 2 |
SHIV, simian–human immunodeficiency virus.
Spectrum of neutralization sensitivity of R5 SHIV strains encoding HIV clade B or C env.
1
Values represent the concentration (µg/ml for soluble CD4 (sCD4) and human nmAbs IgG1b12, 2G12, 2F5, 4E10, or HIVIG) or the dilution (for serum samples) at which relative luciferase units (RLU) were reduced 50% compared to virus control wells. BB47, BB55, BB68, BB75, BB80, BB81, and BB87 are serum samples from individuals infected with HIV-1 clade C. HIVIG, polyclonal high-titer anti-HIV Ig preparation.
2
Data previously published and shown here as reference [19]; given as basis of comparison.